The tumor suppressor characteristics of cyclin‑dependent kinase 10 (CDK10) in nasopharyngeal carcinoma and breast cancer have been previously demonstrated.
The high sensitivity (15/40, 37.5%) and specificity (0% false positives) of detecting CDK10 promoter hypermethylation in NPC patient-derived peripheral blood samples suggest that it could be employed as an epigenetic marker for noninvasive cancer diagnosis and recurrence screening.